Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.47 -0.42 (-3.02%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug ↗

September 25, 2025

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary...

Via Benzinga

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Tesla To Rally More Than 31%? Here Are 10 Top Analyst Forecasts For Friday ↗

September 19, 2025

Via Benzinga

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details ↗

September 19, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Expert Outlook: Intellia Therapeutics Through The Eyes Of 5 Analysts ↗

September 19, 2025

Via Benzinga

Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback ↗

September 18, 2025

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff.

Via Benzinga

Topics ETFs Economy

Intellia Therapeutics Shares Are Ripping Higher: Here's Why ↗

September 18, 2025

Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones.

Via Benzinga

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 18, 2025

Via Benzinga

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday ↗

September 18, 2025

Via Benzinga

Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% ↗

September 11, 2025

These companies are reaching key milestones.

Via The Motley Fool

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews ↗

August 11, 2025

Via Benzinga

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday ↗

August 11, 2025

Via Benzinga

Intellia (NTLA) Q2 Revenue Jumps 106% ↗

August 07, 2025

Via The Motley Fool

Intellia Therapeutics Inc (NASDAQ:NTLA) Q2 2025 Earnings: Revenue Surpasses Estimates, Losses Narrower Than Expected ↗

August 07, 2025

Intellia Therapeutics (NTLA) reported Q2 2025 revenue of $14.25M, beating estimates, with a narrower loss of $0.99 per share. Stock rose 2% pre-market amid strong clinical progress in CRISPR...

Via Chartmill

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 31, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook ↗

July 15, 2025

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

Via MarketBeat

Topics Economy Stocks

FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease ↗

July 07, 2025

KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.

Via Benzinga

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗

June 20, 2025

FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research

Via Benzinga

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday ↗

June 17, 2025

Via Benzinga

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

Assessing Intellia Therapeutics: Insights From 9 Financial Analysts ↗

June 16, 2025

Via Benzinga

Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration ↗

May 30, 2025

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.

Via Benzinga

Topics Government

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 29, 2025

Via Benzinga

Keep an eye on the top gainers and losers in Thursday's session. ↗

May 29, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip ↗

May 29, 2025

The patient’s elevated levels of liver enzymes appear to be resolving without hospitalization or medical intervention, the company said.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.